MTF buys 51% of Bone Biologics, Inc.

 
Bone Biologics, Inc. announced today it had received another round of investment for preferred shares from the Musculoskeletal Transplant Foundation (MTF). MTF now owns 51% of Bone Biologics. As part of the financing, MTF also provided a line of credit to fund continuing operations.  This financial support continues the investments by MTF that have allowed Bone Biologics, Inc. to progress from research through development of the NELL-1 protein sequence UCB-1 to the current culmination of:

Therapeutic validation in non-human primate trials
Economic manufacturing of cGMP grade product
Patent...


Your friends are reading OrthoStreams daily - Are you ?

 

Unlock your access to full rich article, trends, hot startups, market reports and your daily newsletter.

Just $1/day.